DexCom Stock News

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 d

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM us

Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That's because Dexcom (NASDAQ: DXCM ) delivered stronger-than-e

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Mon

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in acc

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, today announced that residents of

Intuitive Surgical will benefit as the need grows for procedures using its robotic devices. DexCom provides critical devices to the increasing population of diabetes patients.

Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes.

In a recent deep-dive research report on the state of the MedTech (medical technology) sector, Oppenheimer highlighted the potential of artificial intelligence (AI) in the sector, noting its capacity

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William B